New drug study aims to ease symptoms and control blood counts in rare blood cancer
NCT ID NCT06743035
First seen Jan 11, 2026 · Last updated Apr 28, 2026 · Updated 14 times
Summary
This study looks at how well ropeginterferon alfa-2b works for adults with polycythemia vera (a rare blood cancer) who do not have an enlarged spleen. Researchers will track symptoms, blood cell levels, and side effects over 36 months in about 200 people. The goal is to see if the drug helps control the disease and improve daily life in a real-world setting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYCYTHEMIA VERA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Onkologisches Studienzentrum Dr. med. Ingo Zander & Dr. med. Eyck von der Heyde
RECRUITINGHanover, Lower Saxony, 30161, Germany
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.